DOUGLAS RICHARD — SEC insider filings
SEC reporting owner CIK 1021015. 28 insider filings on record with FilingPulse; latest filed 2026-11-13.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2021-01-05 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 5 filings — 450,000 shares, $905,820 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 55.
- Largest priced transaction: purchase of 80,000 shares @ $4.32 ($345,480) in MAXCYTE, INC., filed 2023-03-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| MAXCYTE, INC. (MXCT) | Director | 9 | 3 legs · 180,000 sh · $678,920 | — | 9 |
| Aldeyra Therapeutics, Inc. (ALDX) | Director | 8 | 2 legs · 270,000 sh · $226,900 | — | 18 |
| NOVAVAX INC (NVAX) | Director | 11 | — | — | 28 |
Insider filings — DOUGLAS RICHARD
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Purchase (P): 200,000 @ $0.64 | EDGAR |
| 2026-06-23 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 18,880 · Grant/award (A): 21,270 (derivative) @ $0 · Grant/award (A): 14,180 (derivative) @ $0 · Option exercise (M): 18,880 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 70,000 (derivative) @ $0 · Grant/award (A): 19,909 (derivative) @ $0 · Grant/award (A): 2,323 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Purchase (P): 70,000 @ $1.40 | EDGAR |
| 2025-08-13 | 4 | MAXCYTE, INC. (MXCT) | Purchase (P): 80,000 @ $1.39 | EDGAR |
| 2025-06-24 | 4 | NOVAVAX INC (NVAX) | Grant/award (A): 28,326 (derivative) @ $6.42 · Grant/award (A): 18,884 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 10,420 @ $0 · Option exercise (M): 10,420 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 62,728 (derivative) @ $0 · Grant/award (A): 14,476 (derivative) @ $0 · Grant/award (A): 1,689 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 6,670 @ $0 · Option exercise (M): 6,670 (derivative) @ $0 · Grant/award (A): 15,630 (derivative) @ $15.86 · Grant/award (A): 10,420 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 21,367 @ $0 · Grant/award (A): 40,701 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 40,282 (derivative) @ $0 · Grant/award (A): 10,418 (derivative) @ $0 · Grant/award (A): 1,215 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 21,222 (derivative) @ $0 · Grant/award (A): 5,488 (derivative) @ $0 · Grant/award (A): 640 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 3,100 · Option exercise (M): 3,100 (derivative) @ $0 · Grant/award (A): 7,710 (derivative) @ $0 · Grant/award (A): 6,670 (derivative) @ $0 | EDGAR |
| 2023-03-30 | 4 | MAXCYTE, INC. (MXCT) | Purchase (P): 80,000 @ $4.32 | EDGAR |
| 2022-07-08 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 26,900 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 700 · Option exercise (M): 700 (derivative) @ $0 | EDGAR |
| 2022-06-14 | 4 | NOVAVAX INC (NVAX) | Grant/award (A): 4,600 (derivative) @ $0 · Grant/award (A): 3,100 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 53,812 (derivative) @ $0 · Grant/award (A): 13,917 (derivative) @ $0 · Grant/award (A): 1,624 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 1,500 @ $25.60 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2021-11-23 | 4 | MAXCYTE, INC. (MXCT) | Purchase (P): 20,000 @ $11.12 | EDGAR |
| 2021-08-11 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-29 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 3,450 · Option exercise (M): 3,450 (derivative) @ $0 | EDGAR |
| 2021-06-22 | 4 | NOVAVAX INC (NVAX) | Grant/award (A): 1,300 (derivative) @ $0 · Grant/award (A): 700 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 13,534 (derivative) @ $0 · Grant/award (A): 3,500 (derivative) @ $0 · Grant/award (A): 408 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 1,000 @ $50 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1021015 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs